Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab

Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; i...

Full description

Bibliographic Details
Main Authors: Mia Bendix, Anders Dige, Søren Peter Jørgensen, Jens Frederik Dahlerup, Bo Martin Bibby, Bent Deleuran, Jørgen Agnholt
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Nutrients
Subjects:
vitamin D treatment
Crohn’s disease
infliximab
Online Access:https://www.mdpi.com/2072-6643/12/12/3699

Internet

https://www.mdpi.com/2072-6643/12/12/3699

Similar Items